TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less.....

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TATRADER who wrote (10210)	7/13/1999 6:49:00 PM
From: Cary C	Read Replies (2) of 59879

Mark here is the reason for the VPHM move today. cbs.marketwatch.com biz.yahoo.com Among other movers in the biotech sector, shares of ViroPharma (VPHM: news, msgs) jumped nearly 30 percent after the company said its molecule pleconaril reduced the duration and severity in of viral respiratory infection, a severe form of the common cold. There are no antiviral treatments available for the disease, the company said. "This is the first study of an antiviral drug for a severe form of the common cold that has yielded such positive results when the drug was given after the symptoms began," Ronald B. Turner, Head of Pediatric Infectious Diseases, Medical University of South Carolina, who participated in the study, said in a statement. Viral respiratory infection is an upper respiratory infection is often referred to as the common cold. If the infection progresses to the sinuses or lower respiratory tract, it can cause sinusitis, ear infections, bronchitis and pneumonia.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next